Greenbrook TMS Announces Results of Voting at Annual and Special Meeting of Shareholders

Rhea-AI Summary

Greenbrook TMS Inc. (NASDAQ: GBNH) reported the results of its annual and special meeting, where approximately 60.26% of outstanding shares were represented. All director nominees received overwhelming support, with an average of 99.93% votes for their election. KPMG was reappointed as auditor with 99.99% approval. Amendments to the stock option plan and approval of unallocated options received strong backing, with 93.45% votes for both. The company operates 128 TMS therapy centers in the U.S., having administered over 620,000 treatments to more than 17,000 patients.

Positive

• All director nominees were elected with over 99% votes for each.
• KPMG was reappointed as auditor with 99.99% approval.
• 93.45% shareholder approval for amendments to the stock option plan.
• 93.45% approval for unallocated options and share-based awards.
• The company has a growing presence with 128 TMS centers and over 620,000 treatments administered.

Negative

• None.

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today the results of voting at its annual and special meeting of shareholders held earlier today (the “Meeting”). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual and Special Meeting of Shareholders and Management Information Circular of Greenbrook dated May 7, 2021 (the “Circular”).

The total number of common shares represented by holders by proxy at the Meeting was 8,276,984, representing approximately 60.26% of Greenbrook’s outstanding common shares entitled to be voted.

Election of Directors

All of the nominees listed in the Management Information Circular of Greenbrook prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders represented by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed. The following represents the votes received with regard to such matter:

Nominee	Votes For	% Votes For	Votes Withheld	% Votes Withheld
Brian P. Burke	8,168,642	99.93%	5,954	0.07%
Colleen Campbell	8,174,571	100.00%	25	0.00%
Sasha Cucuz	8,174,571	100.00%	25	0.00%
Adrienne Graves, Ph.D.	8,168,771	99.93%	5,825	0.07%
Bill Leonard	8,174,571	100.00%	25	0.00%
Adele C. Oliva	8,168,771	99.93%	5,825	0.07%
Frank Tworecke	8,174,442	100.00%	154	0.00%
Elias Vamvakas	8,174,442	100.00%	154	0.00%

Appointment of Auditors

KPMG LLP was reappointed as auditor of Greenbrook and the directors were authorized to fix the auditor’s remuneration by a resolution passed by a majority of the shareholders represented by proxy at the Meeting. The following represents the votes received with regard to such matter:

Votes For	% Votes For	Votes Withheld	% Votes Withheld
8,276,295	99.99%	689	0.01%

Amendments to the Stock Option Plan

Certain amendments to Greenbrook’s amended and restated stock option plan were approved. The following represents the votes received with regard to such matter:

Votes For	% Votes For	Votes Against	% Votes Against
7,639,438	93.45%	535,158	6.55%

Approval of Unallocated Options and Share-Based Awards

All unallocated Options and Share-Based Awards (as defined in the Circular) under Greenbrook’s amended and restated omnibus equity incentive plan were approved. The following represents the votes received with regard to such matter:

Votes For	% Votes For	Votes Against	% Votes Against
7,639,478	93.45%	535,118	6.55%

About Greenbrook TMS Inc.

Operating through 128 Company-operated treatment centers, Greenbrook is a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 620,000 TMS treatments to over 17,000 patients struggling with depression.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005770/en/

FAQ

What were the voting results for Greenbrook TMS Inc. at the annual meeting?

At the annual meeting, approximately 60.26% of outstanding shares voted, with all director nominees receiving high support, averaging 99.93% votes for their election.

Who was reappointed as auditor for Greenbrook TMS Inc.?

KPMG LLP was reappointed as auditor with 99.99% votes in favor during the annual meeting.

What percentage of shareholders approved the stock option plan amendments for GBNH?

93.45% of shareholders approved the amendments to the stock option plan at the annual meeting.

How many TMS treatments has Greenbrook TMS Inc. administered?

Greenbrook TMS Inc. has provided over 620,000 TMS treatments to more than 17,000 patients.

What is the primary business of Greenbrook TMS Inc.?

Greenbrook TMS Inc. is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the U.S., focusing on treating Major Depressive Disorder and other mental health issues.